Bionaturis chief scientific officer, Dr. Juan Jose Infante, will participate as one of the lecturers in La Rioja’s Innovation Forum. The meeting will be celebrated in the Exhibition and Conference Center of La Rioja the next May 17-18th. Dr. Infante will be lecturing in the ‘Talk Show’ entitled “Bioeconomy and Agro-Food Sector” along with other three experts in this area.

Juan Jose Infante is Phd at Sciences and combines his work leading the development of biological products in Bionaturis with teaching Biotechnology in the Pablo de Olavide University of Seville. He joined Bionaturis in 2007, after a period as senior scientist in the University of Washington in Seattle, USA. In Bionaturis, Dr. Infante has been the principal investigator in the laboratory that developed Bionaturis’ proprietary FLYLIFE platform for manufacturing of biological medicines.

In the previous nine editions, this event has gathered 300 lecturers and more than 7,500 attendants. In this year’s edition, it will address key topics such as alliances of strategic sectors of the Bioeconomy like Food and Agriculture, the reduction of the environmental impact of companies, and potentiation of food control and safety procedures.

Dr. Infante will represent Bionaturis Group, including the matrix company Bionaturis and Biobide and ZIP Solutions. As a general topic, Dr. Infante will address the contribution of the biotech companies in the consolidation of Bioeconomy as a key sector of development. Regarding the Agro-Food, he will review the experience of Bionaturis in developing bio-based innovative solutions for increasing livestock productivity by using preventive measures and immunomodulators, which will lead to a decrease in the use of antibiotics in this sector. Antibiotic resistance has become a serious global health problem. According to the World Health Organization, this situation causes 300,000 deaths every year only in Europe and the USA. The excessive use of antibiotics in human and animal health is behind the continuous emergence of resistant pathogens. All health authorities are looking for urgent solutions to this problem. Bionaturis’ portfolio includes several products addressing this problem, like BNT006, a functional ingredient able to specifically boost immunity of production animals, leading to an average increase in productivity. BNT006 is already available in a commercial format for poultry and swine. Bionaturis is currently working in partnership with the Agro-Food company COVAP in the project “Bovihealth” with the aim of translating this solution to the bovine sector.

Bionaturis, with about fifteen products in developments in its portfolio, is working in addressing other problems in animal health, like prevention of diseases caused by parasites in pets and livestock, or vaccines against viral and bacterial infections for swine, poultry and fish.

For further information about the event, this is the link to its website

About Bionaturis Group

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).